Lumena Pharmaceuticals Inc.
Repurposing a cholesterol drug candidate for cholestatic liver disease
This article was originally published in Start Up
Executive Summary
Lumena Pharmaceuticals Inc. is converting a compound previously tested as a cholesterol-lowering agent into an experimental treatment for cholestatic liver diseases. The molecule inhibits a so-called transporter that normally helps the body recycle bile acid.